
MC-38-CEA Cell Lines - Kerafast
MC-38-CEA cells, clone 1 and 2 derived from C57BL6 murine colon adenocarcinoma engineered to express human carcinoembryonic antigen (CEA). Buy Here!
Tumor regression and immunity in combination therapy with anti-CEA …
Anti-CEA CAR vs. mock transduced T cells delayed the median survival of CEA transfected s.c. MC38 or orthotopic E0771 tumor-bearing CEATg mice by 2 days.
Differential combination immunotherapy requirements for inflamed …
Results: The MC38-CEA and 4T1 tumor models have differential sensitivities to the combination treatments. In the 'warm' MC38-CEA, combinations with two to five agents resulted in …
Tumor regression and immunity in combination therapy with anti-CEA ...
Mar 18, 2021 · With the addition of one-day prior cyclophosphamide (CY) lymphodepletion, anti-CEA CAR T cell treatment delayed the median survival of MC38/CEA and E0771/CEA tumor …
Novel neoantigen peptides and tumor regression in the MC38 …
Aug 3, 2023 · Amongst the 10 peptides tested, we picked five that elicited greatest IFNγ secretion in re-stimulated splenocytes. Predicted binding affinity did not correlate with in-vivo …
MC-38 Cell Line - Kerafast
MC-38 Cell Line derived from C57BL6 murine colon adenocarcinoma cells. From the laboratories of James W. Hodge, PhD, MBA and Jeffrey Schlom, PhD, National Cancer Institute/NIH. This …
MC38 colorectal tumor cell lines from two different sources …
MC38 is among the most commonly used tumor models for colorectal carcinoma and can be regarded as a “workhorse” for cancer immunotherapy research. Accordingly, MC38 is currently …
Comparison of MC38-CEA tumor growth characteristic after subcutaneous vs. subQperior implantation shows more homogenous growth and larger tumor volumes after subQperior …
"Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal ... - PubMed
These data are consistent with the hypothesis that pH-dependent CEA binding allows mAb dissociation from target in acidified endosomes, enabling FcRn-mediated protection from …
Differential combination immunotherapy requirements for …
Feb 18, 2021 · The MC38-CEA and 4T1 tumor models have differential sensitivities to the combination treatments. In the ‘warm’ MC38-CEA, combinations with two to five agents …